Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer

Prostate

Volumn 74, Issue 12, 2014, Pages 1199-1208

  Udager, Aaron M ^a   Shi, Yang ^b,c   Tomlins, Scott A ^a,c   Alva, Ajjai ^a,c   Siddiqui, Javed ^c   Cao, Xuhong ^c   Pienta, Kenneth J ^d   Jiang, Hui ^b   Chinnaiyan, Arul M ^a,c,e   Mehra, Rohit ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

androgen receptor (AR); fluorescent in situ hybridization (FISH); immunohistochemistry (IHC); rapid autopsy; TMPRSS2 ERG

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ARTICLE; AUTOPSY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; MALE; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR CELL;

ANDROGEN RECEPTOR (AR); FLUORESCENT IN SITU HYBRIDIZATION (FISH); IMMUNOHISTOCHEMISTRY (IHC); RAPID AUTOPSY; TMPRSS2-ERG;

AUTOPSY; COHORT STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; KALLIKREINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS;

EID: 84904663116     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22836     Document Type: Article

References (29)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
2. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM,. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448 (7153): 595-599.
3. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8 (7): 497-511.
4. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM,. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10 (2): 177-188.
5. Brenner JC, Chinnaiyan AM, Tomlins SA,. ETS fusion genes in prostate cancer. In:, Tindall DJ, editor. Prostate cancer: Biochemistry, molecular biology and genetics, protein reviews. New York: Springer; 2013.
6. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB,. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007; 67 (17): 7991-7995.
7. Barry M, Perner S, Demichelis F, Rubin MA,. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 2007; 70 (4): 630-633.
8. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB,. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20 (5): 538-544.
9. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68 (10): 3584-3590.
10. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA,. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12 (7): 590-598.
11. Gopalan A, Leversha MA, Dudas ME, Maschino AC, Chang J, Al-Ahmadie HA, Chen YB, Tickoo SK, Reuter VE, Fine SW,. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: Incidence and correlation with ERG immunohistochemistry. Histopathology 2013; 63 (2): 279-286.
12. Teng LH, Wang C, Begin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA,. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology 2013; 82 (2): 394-399.
13. Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C,. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17 (2): 126-131.
14. Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Comperat E, Cheng L,. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: The superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013; 44 (10): 2227-2233.
15. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ,. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24 (6): 820-828.
16. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA,. Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005; 4 (5): 548-554.
17. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ,. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000; 6 (3): 1038-1045.
18. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ,. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004; 64 (24): 9209-9216.
19. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ,. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011; 17 (12): 3924-3932.
20. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA,. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487 (7406): 239-243.
21. Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P,. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol 2012; 25 (3): 378-387.
22. Li Z, Chen CJ, Wang JK, Hsia E, Li W, Squires J, Sun Y, Huang J,. Neuroendocrine differentiation of prostate cancer. Asian J Androl 2013; 15 (3): 328-332.
23. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y,. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006; 66 (13): 1399-1406.
24. Slovin SF,. Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing ? Nat Clin Pract Urol 2006; 3 (3): 138-144.
25. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA,. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1 (6): 487-495.
26. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC,. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227 (3): 286-297.
27. Udager AM, Alva A, Mehra R,. Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. Cancer J 2014; 20 (1): 29-42.
28. Roychowdhury S, Chinnaiyan AM,. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013; 31 (15): 1866-1873.
29. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM,. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19 (5): 664-678.